Centeon buying albumin from other sources to fill Albuminar contracts during recall period.
CENTEON BUYING ALBUMIN FROM OTHER SOURCES TO FILL CONTRACTS until shipments of Centeon's human albumin product Albuminar resume following the company's recall of all lots. "About half of Albuminar sales are to contract customers," Rhone-Poulenc Rorer VP-Investor Relations Arvind Sood told an Oppenheimer & Co. health care conference in New York City Oct. 28. Centeon is a joint venture of RPR and Hoechst. "Centeon is currently buying competitors' products on the spot market to make sure that...we are able to satisfy many of these contractual agreements and to retain customer loyalty," Sood continued.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth